# AMJEVITA® (adalimumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/adalimumab

> The FDA approved AMJEVITA® (adalimumab), sponsored by AbbVie Inc. (ABBV), on October 20, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is AMJEVITA® (adalimumab) FDA approved?

Yes. The FDA approved AMJEVITA® (adalimumab), sponsored by AbbVie Inc. (ABBV), on October 20, 2026. Press release filed with the SEC (EX-99): "REYKJAVIK, Iceland and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alvotech's biosimilar to Humira® (adalimumab)." [Calendar and source filings](https://sec-api.dev/pdufa/adalimumab)

Source: Press release filed with the SEC (EX-99), accession 0001171843-26-006704, https://www.sec.gov/Archives/edgar/data/1898416/000117184326006704/exh_991.htm (retrieved 2026-11-12). Last confirmed 2026-10-20. Cite: https://sec-api.dev/pdufa/adalimumab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | AMJEVITA® (adalimumab) |
| Codes |  |
| Sponsor | AbbVie Inc. (ABBV) https://sec-api.dev/companies/abbv/catalysts |
| Indications | [Ulcerative Colitis](https://sec-api.dev/indications/ulcerative-colitis), [Juvenile Psoriatic Arthritis](https://sec-api.dev/indications/juvenile-psoriatic-arthritis) |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### December 16, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125057 SUPPL-419 (Efficacy): submission_status AP, submission_status_date 20201216, review_priority STANDARD; sponsor_name ABBVIE INC; product HUMIRA (ADALIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125057%22

### February 24, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125057 SUPPL-417 (Efficacy): submission_status AP, submission_status_date 20210224, review_priority STANDARD; sponsor_name ABBVIE INC; product HUMIRA (ADALIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125057%22

### Feb 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-01-27, last confirmed 2025-05-27.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000421): "In February 2024, the FDA approved SIMLANDI® (adalimumab-ryvk), the first high-concentration, citrate-free interchangeable biosimilar to Humira® (adalimumab)." https://www.sec.gov/Archives/edgar/data/1898416/000117184325000421/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-003438): "In February 2024 , the FDA approved AVT 02 as an interchangeable high - concentration, citrate - free biosimilar to Humira ." https://www.sec.gov/Archives/edgar/data/1898416/000117184325003438/exh_992.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-002743): "In February 2024, the FDA approved SIMLANDI® (adalimumab-ryvk), the first high-concentration, citrate-free interchangeable biosimilar to Humira® (adaliumumab), which was launched in the U.S. in May 2024." https://www.sec.gov/Archives/edgar/data/1898416/000117184325002743/exh_991.htm
- SEC Form 10-K (accession 0001628280-25-015052): "•In February 2024, the Company announced that the U.S. Food and Drug Administration (FDA) has approved Simlandi (adalimumab) injection, the AVT02 interchangeable biosimilar to Humira." https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm

### February 24, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-01-29, last confirmed 2025-01-29.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000493): "On February 24, 2024, Alvotech and Teva announced that the FDA approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira®, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn's disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis." https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/exh_991.htm

### September 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Juvenile Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06100744 (A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06100744

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Juvenile Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06100744 (A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06100744

### October 5, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-10-05, last confirmed 2026-10-05.
- Press release filed with the SEC (EX-99) (accession 0001171843-26-006383): "REYKJAVIK, Iceland, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Biologics License Application (BLA) for AVT02 (adalimumab-ryvk), marketed in the U.S. as SIMLANDI®, enabling drug substance for the product to be manufactured in a second production suite at the company's Reykjavik facility." https://www.sec.gov/Archives/edgar/data/1898416/000117184326006383/exh_991.htm

### October 20, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-10-20, last confirmed 2026-10-20.
- Press release filed with the SEC (EX-99) (accession 0001171843-26-006704): "REYKJAVIK, Iceland and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alvotech's biosimilar to Humira® (adalimumab)." https://www.sec.gov/Archives/edgar/data/1898416/000117184326006704/exh_991.htm

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06257875 (A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06257875

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06257875 (A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06257875

## Same indication

- [ABX464](https://sec-api.dev/pdufa/abx464) (ABVX)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Emvistegrast](https://sec-api.dev/pdufa/emvistegrast) (GILD)
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart) (MRK)
- [Mirikizumab](https://sec-api.dev/pdufa/mirikizumab) (LLY)
- [Mirikizumab iv](https://sec-api.dev/pdufa/mirikizumab-iv) (LLY)
- [Nx-13 250mg](https://sec-api.dev/pdufa/nx-13) (ABBV)
- [Obefazimod](https://sec-api.dev/pdufa/obefazimod) (ABVX)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [SPY001](https://sec-api.dev/pdufa/spy001) (SYRE)
- [Tilpisertib fosmecarbil](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) (GILD)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Xeljanz (tofacitinib citrate)](https://sec-api.dev/pdufa/tofacitinib) (PFE)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)
- [Vedolizumab iv](https://sec-api.dev/pdufa/vedolizumab-iv) (TAK)
- [Vedolizumab sc](https://sec-api.dev/pdufa/vedolizumab-sc) (TAK)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zotemtegrast](https://sec-api.dev/pdufa/zotemtegrast) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/adalimumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AMJEVITA® (adalimumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/adalimumab

```bibtex
@misc{secapidev_pdufa_adalimumab_20261116,
  title        = {AMJEVITA® (adalimumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/adalimumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_adalimumab_20261116","title":"AMJEVITA® (adalimumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/adalimumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
